Spheroid-forming subpopulation of breast cancer cells demonstrates vasculogenic mimicry via hsa-miR-299–5p regulated de novo expression of osteopontin

The growth of cancer cells as multicellular spheroids has frequently been reported to mimic the in vivo tumour architecture and physiology and has been utilized to study antitumour drugs. In order to determine the distinctive characteristics of the spheroid‐derived cells compared to the corresponding monolayer‐derived cells, we enriched multicellular spheroid‐forming subpopulations of cells from three human breast cancer cell lines (MCF7, MCF10AT and MCF10DCIS.com). These spheroid‐derived cells were injected into female athymic nude mice to assess their tumorigenic potential and were profiled for their characteristic miRNA signature. We discovered that the spheroid‐derived cells expressed increased levels of osteopontin (OPN), an oncogenic protein that has been clinically correlated with increased tumour burden and adverse prognosis in patients with breast cancer metastasis. Our studies further show that increased OPN levels are brought about in part, by decreased levels of hsa‐mir‐299–5p in the spheroid‐forming population from all three cell lines. Moreover, the spheroid‐forming cells can organize into vascular structures in response to nutritional limitation; these structures recapitulate a vascular phenotype by the expression of endothelial markers CD31, Angiopoeitin‐1 and Endoglin. In this study, we have validated that hsa‐mir‐299–5p targets OPN; de novo expression of OPN in turn plays a critical role in enhancing proliferation, tumorigenicity and the ability to display vasculogenic mimicry of the spheroid‐forming cells.

[1]  J. Winstanley,et al.  Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. , 2002, Cancer research.

[2]  V. Castronovo,et al.  Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. , 1995, The American journal of pathology.

[3]  R Folberg,et al.  Vasculogenic mimicry and tumor angiogenesis. , 2000, The American journal of pathology.

[4]  F. O'Malley,et al.  Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  James P. Freyer,et al.  The Use of 3-D Cultures for High-Throughput Screening: The Multicellular Spheroid Model , 2004, Journal of biomolecular screening.

[6]  A. Chambers,et al.  Enhanced cell surface CD44 variant (v6, v9) expression by osteopontin in breast cancer epithelial cells facilitates tumor cell migration: Novel post-transcriptional, post-translational regulation , 2006, Clinical & Experimental Metastasis.

[7]  Olga Kovalchuk,et al.  Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin , 2008, Molecular Cancer Therapeutics.

[8]  J. Lee,et al.  Expression of osteopontin and osteonectin in breast cancer. , 1998, Journal of Korean medical science.

[9]  K. Laderoute,et al.  Enhancement of transforming growth factor-a . synthesis in multicellular tumour spheroids of A 431 squamous carcinoma cells , 2022 .

[10]  G. Kundu,et al.  The crucial role of cyclooxygenase-2 in osteopontin-induced protein kinase C alpha/c-Src/IkappaB kinase alpha/beta-dependent prostate tumor progression and angiogenesis. , 2006, Cancer research.

[11]  Miao Sun,et al.  MicroRNA and cancer: Current status and prospective , 2006, International journal of cancer.

[12]  Chang-Zheng Chen,et al.  MicroRNAs as oncogenes and tumor suppressors. , 2005, The New England journal of medicine.

[13]  A. Alessandrini,et al.  Suppression of human melanoma metastasis by the metastasis suppressor gene, BRMS1. , 2002, Experimental cell research.

[14]  G. Kundu,et al.  Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. , 2008, Cancer research.

[15]  R. Sutherland Cell and environment interactions in tumor microregions: the multicell spheroid model. , 1988, Science.

[16]  B. Desoize,et al.  Cell culture as spheroids: an approach to multicellular resistance. , 1998, Anticancer research.

[17]  Catherine Charbonnel,et al.  Prediction of metastatic relapse in node-positive breast cancer: establishment of a clinicogenomic model after FEC100 adjuvant regimen , 2008, Breast Cancer Research and Treatment.

[18]  V. Bramwell,et al.  The functional and clinical roles of osteopontin in cancer and metastasis. , 2001, Current molecular medicine.

[19]  L. Rodrigues,et al.  The Role of Osteopontin in Tumor Progression and Metastasis in Breast Cancer , 2007, Cancer Epidemiology Biomarkers & Prevention.

[20]  G. Dontu,et al.  In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. , 2003, Genes & development.

[21]  K. Hruska,et al.  The Integrin {alpha}v{beta}3 and CD44 Regulate the Actions of Osteopontin on Osteoclast Motility , 2003, Calcified Tissue International.

[22]  Y. Yatabe,et al.  Reduced Expression of the let-7 MicroRNAs in Human Lung Cancers in Association with Shortened Postoperative Survival , 2004, Cancer Research.

[23]  Michael J Kerin,et al.  MicroRNAs as Prognostic Indicators and Therapeutic Targets: Potential Effect on Breast Cancer Management , 2008, Clinical Cancer Research.

[24]  Barbara McGrogan,et al.  Taxanes, microtubules and chemoresistant breast cancer. , 2008, Biochimica et biophysica acta.

[25]  V. Ambros microRNAs Tiny Regulators with Great Potential , 2001, Cell.

[26]  Fred R. Miller,et al.  Malignant MCF10CA1 Cell Lines Derived from Premalignant Human Breast Epithelial MCF10AT Cells , 2004, Breast Cancer Research and Treatment.

[27]  J. Brugge,et al.  Use of Three-Dimensional Basement Membrane Cultures to Model Oncogene-Induced Changes in Mammary Epithelial Morphogenesis , 2004, Journal of Mammary Gland Biology and Neoplasia.

[28]  G. Goodall,et al.  The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1 , 2008, Nature Cell Biology.

[29]  R. Kerbel,et al.  TGF-β gene expression depends on tissue architecture , 1993, In Vitro Cellular & Developmental Biology - Animal.

[30]  W. Cho OncomiRs: the discovery and progress of microRNAs in cancers , 2007, Molecular Cancer.

[31]  M. Okazaki,et al.  Osteopontin-derived peptide SVVYGLR induces angiogenesis in vivo. , 2004, Dental materials journal.

[32]  R. Samant,et al.  Elevated levels of Ser/Thr protein phosphatase 5 (PP5) in human breast cancer. , 2008, Biochimica et biophysica acta.

[33]  Chris Jay,et al.  miRNA profiling for diagnosis and prognosis of human cancer. , 2007, DNA and cell biology.

[34]  G. Kundu,et al.  Osteopontin Induces Nuclear Factor κB-mediated Promatrix Metalloproteinase-2 Activation through IκBα/IKK Signaling Pathways, and Curcumin (Diferulolylmethane) Down-regulates These Pathways* , 2003, The Journal of Biological Chemistry.

[35]  G. Kundu,et al.  Osteopontin induces nuclear factor kappa B-mediated promatrix metalloproteinase-2 activation through I kappa B alpha /IKK signaling pathways, and curcumin (diferulolylmethane) down-regulates these pathways. , 2003, The Journal of biological chemistry.

[36]  D. Medina,et al.  Re-evaluation of mammary stem cell biology based on in vivo transplantation , 2008, Breast Cancer Research.

[37]  Susan G Hilsenbeck,et al.  Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. , 2008, Journal of the National Cancer Institute.

[38]  V. Bramwell,et al.  Serial Plasma Osteopontin Levels Have Prognostic Value in Metastatic Breast Cancer , 2006, Clinical Cancer Research.

[39]  D. Denhardt,et al.  Soluble osteopontin inhibits apoptosis of adherent endothelial cells deprived of growth factors * , 2002, Journal of cellular biochemistry.

[40]  C. Ries,et al.  Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab , 2009, Oncogene.

[41]  B. Teicher,et al.  Acquired multicellular-mediated resistance to alkylating agents in cancer. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[42]  I. Tannock,et al.  Drug penetration in solid tumours , 2006, Nature Reviews Cancer.

[43]  A. Sundan,et al.  Role of osteopontin in adhesion, migration, cell survival and bone remodeling. , 2004, Experimental oncology.

[44]  J. Rak Is cancer stem cell a cell, or a multicellular unit capable of inducing angiogenesis? , 2006, Medical hypotheses.

[45]  A. Chambers,et al.  The Role of Osteopontin in Breast Cancer: Clinical and Experimental Studies , 2001, Journal of Mammary Gland Biology and Neoplasia.

[46]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[47]  G. Kundu,et al.  The Crucial Role of Cyclooxygenase-2 in Osteopontin-Induced Protein Kinase C α/c-Src/IκB Kinase α/β–Dependent Prostate Tumor Progression and Angiogenesis , 2006 .

[48]  K. Nishio,et al.  Osteopontin overproduced by tumor cells acts as a potent angiogenic factor contributing to tumor growth. , 2003, Cancer letters.

[49]  G. Weiss,et al.  MicroRNAs and cancer: past, present, and potential future , 2008, Molecular Cancer Therapeutics.

[50]  N. Fedarko,et al.  Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[51]  Weiyun Zhu,et al.  Impact of tiny miRNAs on cancers. , 2007, World journal of gastroenterology.

[52]  J. F. Harris,et al.  Osteopontin expression in a group of lymph node negative breast cancer patients , 1998, International journal of cancer.

[53]  M. Hendrix,et al.  Molecular biology of breast cancer metastasis Molecular expression of vascular markers by aggressive breast cancer cells , 2000, Breast Cancer Research.

[54]  Y. Pekarsky,et al.  The role of microRNA and other non-coding RNA in the pathogenesis of chronic lymphocytic leukemia. , 2007, Best practice & research. Clinical haematology.

[55]  M. Daidone,et al.  Breast cancer stem cells: an overview. , 2006, European journal of cancer.

[56]  R. Wechsler-Reya,et al.  Hit 'em where they live: targeting the cancer stem cell niche. , 2007, Cancer cell.

[57]  Kornelia Polyak,et al.  Breast cancer: origins and evolution. , 2007, The Journal of clinical investigation.

[58]  S. Philip,et al.  Osteopontin Stimulates Tumor Growth and Activation of Promatrix Metalloproteinase-2 through Nuclear Factor-κB-mediated Induction of Membrane Type 1 Matrix Metalloproteinase in Murine Melanoma Cells* , 2001, The Journal of Biological Chemistry.

[59]  K. Polyak Is Breast Tumor Progression Really Linear? , 2008, Clinical Cancer Research.

[60]  C. Croce,et al.  MicroRNA gene expression deregulation in human breast cancer. , 2005, Cancer research.

[61]  A. Waage,et al.  Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma. , 2004, Haematologica.

[62]  J. F. Harris,et al.  Osteopontin expression in lung cancer. , 1996, Lung cancer.

[63]  G. Weber,et al.  An osteopontin splice variant induces anchorage independence in human breast cancer cells , 2006, Oncogene.

[64]  R. Kerbel,et al.  Multicellular resistance: a new paradigm to explain aspects of acquired drug resistance of solid tumors. , 1994, Cold Spring Harbor symposia on quantitative biology.

[65]  Tyler E. Miller,et al.  MicroRNA-221/222 Confers Tamoxifen Resistance in Breast Cancer by Targeting p27Kip1*♦ , 2008, Journal of Biological Chemistry.

[66]  R. Kerbel,et al.  Multicellular gastric cancer spheroids recapitulate growth pattern and differentiation phenotype of human gastric carcinomas. , 2001, Gastroenterology.

[67]  G. Casey,et al.  Osteopontin Knockdown Suppresses Tumorigenicity of Human Metastatic Breast Carcinoma, MDA-MB-435 , 2006, Clinical & Experimental Metastasis.

[68]  Massimo Negrini,et al.  Breast cancer metastasis: a microRNA story , 2008, Breast Cancer Research.

[69]  V. Ambros,et al.  The regulation of genes and genomes by small RNAs , 2007, Development.

[70]  A. Ivascu,et al.  Diversity of cell-mediated adhesions in breast cancer spheroids. , 2007, International journal of oncology.

[71]  M. O'hare,et al.  Three-dimensional in vitro tissue culture models of breast cancer — a review , 2004, Breast Cancer Research and Treatment.

[72]  Lin Zhang,et al.  The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis , 2008, Nature Cell Biology.

[73]  Domenico Coppola,et al.  MicroRNA-221/222 Negatively Regulates Estrogen Receptorα and Is Associated with Tamoxifen Resistance in Breast Cancer* , 2008, Journal of Biological Chemistry.

[74]  Mansoor M Ahmed,et al.  The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis. , 2006, Current molecular medicine.

[75]  M. Clarke,et al.  Self-renewal and solid tumor stem cells , 2004, Oncogene.

[76]  F. Miller,et al.  MCF10DCIS.com xenograft model of human comedo ductal carcinoma in situ. , 2000, Journal of the National Cancer Institute.

[77]  Linheng Li,et al.  Normal stem cells and cancer stem cells: the niche matters. , 2006, Cancer research.

[78]  W. Gerald,et al.  Endogenous human microRNAs that suppress breast cancer metastasis , 2008, Nature.

[79]  F. Miller,et al.  Progression of Premalignant MCF10AT Generates Heterogeneous Malignant Variants with Characteristic Histologic Types and Immunohistochemical Markers , 2000, Breast Cancer Research and Treatment.

[80]  S. North,et al.  Recent developments in the regulation of the angiogenic switch by cellular stress factors in tumors. , 2005, Cancer letters.

[81]  R. Weinberg,et al.  Tumour invasion and metastasis initiated by microRNA-10b in breast cancer , 2007, Nature.